What smart money is saying about Guardant Health, Inc.
3 funds in our archive have pitched Guardant Health, Inc. — most recently Brown Advisory Mid‑Cap Growth in March 2026.
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Get an email when a fund writes about it
Position history
Between Q4 2025 and Q2 2026, 6 fund letters reported a position in Guardant Health, Inc. — 4 opened or added to the position.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 4 | 2 | 0 | 0 |
| Q1 2026 | 2 | 2 | 0 | 2 |
| Q4 2025 | 0 | 0 | 0 | 1 |
Fund activity · 6 positions · 4 moves
- New positionClearBridge Investments SMID Cap Growth StrategyJune 2026
“Health care activity included a new position in Guardant Health.”
Read the letterGuardant Health, Inc. - AddedArtisan Partners U.S. Mid‑Cap Growth StrategyJune 2026
“In addition to Lattice Semiconductor and Comfort Systems, we also added to Guardant Health, Teledyne Technologies and Tradeweb Markets during the quarter.”
Read the letterGuardant Health, Inc. - HoldsAlger.com Alger Small Cap Focus FundJune 2026
“Nebius Group, Credo Technology Group, and Guardant Health, Inc. were among the top contributors to performance.”
Read the letterGuardant Health, Inc. - HoldsBaron Health Care FundJune 2026
“Strength in life sciences tools & services was widespread, led by BillionToOne, Inc. and Guardant Health, Inc.”
Read the letterGuardant Health, Inc. - New positionBrown Advisory U.S. Small-Cap Blend UCITS FundMarch 2026
“we purchased shares of Guardant Health, Inc. (GH), as recent due diligence highlighted a stable competitive environment and underscored a number of positive catalysts for the company over the next several years.”
Read the letterGuardant Health, Inc. - New positionBrown Advisory Mid‑Cap GrowthMarch 2026
“After following the company for many years, we built a small position in Guardant Health after recent due diligence highlighted a stable competitive environment and underscored several positive upcoming catalysts for the company.”
Read the letterGuardant Health, Inc.
Also mentioned · 1
These funds discuss Guardant Health, Inc. — as a competitor, benchmark or comparable — without disclosing a position in it.
- MentionedArtisan Partners U.S. Small-Cap Growth StrategyJune 2026
“We saw strong earnings and stock performance from biotech drug companies such as Rhythm Pharmaceuticals, as well as life sciences tools and diagnostics innovators including Twist Bioscience, Guardant Health and Veracyte.”
Read the letterGuardant Health, Inc.
Fund coverage · 3 theses
- Brown Advisory Mid‑Cap GrowthMarch 2026
Guardant Health has a stable competitive backdrop and multiple upcoming catalysts across screening, commercial expansion, and reimbursement.
Read the full thesis - Baron Health Care FundMarch 2026
Guardant Health is a leading diagnostics company with multiple large growth markets and a long runway for revenue expansion.
Read the full thesis - Artisan U.S. Small-Cap Growth StrategyDecember 2025
Guardant Health Inc is a liquid biopsy leader with a dominant tumor-naïve MRD position and expansion into tumor-informed testing.
Read the full thesis
Read every full thesis on Guardant Health, Inc.
Unlock all 3 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→